Prevalence of Chronic Oral GVHD in a Cohort of Egyptian Pediatric Patients Following Allogenic Hemopoietic Stem Cell Transplantation

Document Type : Original Article

Authors

Oral Medicine and Periodontology Department, Faculty of Dentistry, Cairo University, Cairo, Egypt

Abstract

Aim:  The current research  aims at screening a cohort of  Egyptian pediatric patients after receiving allogenic hemopoietic stem cell transplant (HSCT) in order  to detect prevalence and risk factors of oral chronic graft versus host disease (cGVHD).
Methodology: This study extended for a period of six months and included 47 children who had undergone HSCT at least three months prior to the study at Nasser Institute for Research and Treatment Hospital. The patients were screened for possible oral pathological manifestations. A questionnaire was completed identifying age, sex, type of transplant, conditioning regimen, occurrence of acute GVHD and systemic cGVHD, while unstimulated salivary flow rate and maximum mouth opening were measured.
Results: The results revealed that the number of patients who manifested cGVHD in relation to the whole study population is 32 patients (68.08%). In relation to the whole study population, the number of  patients with oral cGVHD was 26 (55.3%). There was no statistically significant association between appearance of oral cGVHD and most of the investigated risk factors (age ,sex, type of transplant , conditioning, occurrence of acute GVHD P value > 0.05. A significant association was detected between  occurrence of oral cGVHD and systemic cGVHD (mainly skin ) p value < 0.05.
Conclusion: In a sample of Egyptian pediatric patients who underwent HSCT, oral cGVHD is most prevalent among patients with cGVHD  affecting (81.2%) of them. Also the appearance of combined oral  manifestations is common. Appearance of systemic and oral manifestations of cGVHD were significantly associated. 

Keywords

Main Subjects


 


 

 

Introduction

  Hemopoietic stem cells transplantation (HSCT) refers to procedures by which haematopoietic stem cells of any source and from any donor type are donated to a recipient in order to help in repopulating and changing the haematopoietic system totally or partially . Bone marrow (BM), peripheral blood (PB), or cord blood (CB) are representing the sources of stem cells for HSCT Sureda et al. (2015).  HSCT is presently considered the standard management procedure for many hematological disorders Juric et al. (2016)

 According to data from the latest analysis of  the Center of International Blood and Marrow Transplant Research (CIBMTR), the estimated annual number of allogeneic transplant recipients  exceeded almost  8,000 cases per  year in the US in 2013 with 9,498 transplants estimated in 2019 Phelan et al. (2020). Whereas, in Egypt, for a period of 30 years of experience (from 1997 to 2017), 4256 transplants  were conducted  60% of which were allogenic Mahmoud et al. (2020).

In children and adolescents, allogeneic HSCT represents about 20% of all allogeneic HSCT practice , especially in rare and congenital diseases Sureda et al. (2015).

In 2020, the population of Egypt surpassed 100 million. There are fifteen transplant centers, where the transplant rate is 8.4 per million Mahmoud et al. (2020), this rate is considered higher than the rate previously reported in 2008, which was 2.8 per million  Mahmoud et al. (2008).  

Following allogenic HSCT, chronic graft-versus-host disease cGVHD is considered the most eminent non-relapse reason of morbidity and mortality (Grube et al.2016).  After allogenic HSCT, the incidence of cGVHD is almost 50% among all adult and pediatric patients who  received allogenic bone marrow transplant to manage acute leukemia, chronic leukemia and myelodysplastic syndrome  Arai et al. (2015).

Chronic GVHD persists for months or years. Eyes, oral cavity, GIT, liver, genitourinary tract, lungs and joints are the common sites of affection Schubert& Correa. (2008) and Fassil et al. (2012). Oral cGVHD  causes comorbidity manifested as pain and discomfort affecting general oral health status , functional abilities , and quality of  life in the patients Meier et al. (2011); Fassil et al. (2012) and Bassim et al. (2014).

 The clinical presentation of oral cGVHD  is variable. Oral manifestations occur at any site in the oral tissues. Oral mucosal lesions are present as erythema, ulcers, lichenoid lesions , and mucoceles in addition to xerostomia and sclerosis  Filipovich et al. (2005) and Pavletic et al. (2006). Oral affection affects quality of life of the patients as explained before . Therefore, the present study aims to detect the prevalence and predict risk factors for developing oral cGVHD after bone marrow transplant in a sample of Egyptian children.

 


 

Subjects and Methods

This is a cross - sectional study that  was conducted at Nasser Institute for Research and Treatment for pediatric patients undergoing allogeneic HSCT starting from June 2019 to December 2019. ClinicalTrials.gov Identifier: NCT03880214

1- Participants:

Children aged between 3 and 18 years old  who received  bone marrow transplantation at least 3 months  prior to conduction of the study , participants diagnosed with a neoplastic or non- neoplastic diseases can be included. The participants in the sample received cyclosporine (sandimmune) as immunomodulatory for prevention and treatment of GVHD, while patients (or their guardians) who do not approve to join the study or children receiving chemo or radiotherapy are excluded .

1.1 Ethical considerations:

This research had been approved by the ethical committee of the Faculty of Dentistry, Cairo University. Approval No. (11 7 18). Guardians of the children that met the inclusion criteria signed a consent form in Arabic approving their children to participate in the study. All the data needed were discussed.

2- Data collection

2.1 Study variables

-      Exposure: Exposure to hemopoietic stem cells transplantation.

-      Outcomes: Oral mucosal alteration, Salivary glands function and Maximal mouth opening.

-      Risk factors: Age, Gender, Type of stem cell, Previous acute attack of GVHD, conditioning regimen dose of CD34 and other organ involvement.

The data collected through:  

2.2 A standardized Transplant Database Questionnaire as mentioned in Hull et al. (2011)

 

2.3  Clinical examination:

2.3.1 Comprehensive intraoral clinical examination for the soft tissue under good lightening condition to detect any abnormalities. The oral lesions were recorded as oral mucosal alterations as listed by Treister et al. (2005) in the form of presence of variant oral lichen planus and oral lichenoid reactions, ulcers, erythema  or mucocele.

  2.3.2 Salivary glands function:

-      Assessed by measuring the resting salivary flow rate Walter et al. (2001), saliva collection was done while the patients were sitting down; their heads were tilted forward, they were instructed not to swallow or move their  tongues or lips, and their eyes were kept open. Any preexisting saliva was swallowed before the collection.

-      At the end of the collection time, Saliva was spitted in a container, then the volume was measured   and finally salivary flow rate was determined (in milliliters per minute). Children should be closely monitored to prevent them from swallowing and to prevent any  sample loss throughout the collection period. If this happened, the procedure is repeated at least 30 minutes after the first attempt.

-      We classified the examined children into normal and diminished unstimulated salivary flow rate according to findings by  by  Forcella et al. who reported that  unstimulated  salivary flow rate in healthy children ranged from (0.49, 1.05) ml/min  (Forcella et al. 2018)

-       

2.3.3 Maximal mouth opening estimation:

 The distance between upper and lower teeth was measured in millimeters from the incisal edge of the most vertically aligned maxillary central incisor to the labio-incisal edge of the opposing mandibular incisor using a caliber. The measurements taken were used to classify  subjects according to their degree of opening and their ages into ( normal or restricted ) according to the measurements reported in Müller et al. , they  plotted the average maximum mouth opening versus the age    (Müller et al. 2011)

 

3- Data management:

All  information obtained from the participants was stored in locked files in a limited access area. All data collection, process, and administrative forms were identified by a coded ID (Identification Number).

4- Sources of Bias:

-Selection bias was  minimized by enrolling the eligible participants in the study in a consecutive order of hospital visits. Concerning non-respondent bias, explaining the aim of the study and the importance to the participants helps to decrease it. For incomplete records, statistical analysis included them with reporting the cause of not completing the record.

5- Statistical methods:

Data were coded and entered using the statistical package for the Social Sciences (SPSS) version 26 (IBM Corp., Armonk, NY, USA).  Data were presented using mean, standard deviation, median, minimum and maximum in quantitative data and using frequency (count) and relative frequency (percentage) for categorical data. To compare  between quantitative variables the non-parametric Mann-Whitney test was used. To compare categorical data, Chi square (χ2) test was used. In case of presence of association, logistic regression was done to detect independent predictors of oral GVHD. P-values less than 0.05 were considered as statistically significant

 


 

 

Results

A total of 47 patients (31 male and 16 female) who underwent bone marrow transplantation were recruited for a 6 month duration from June 2019 to December 2019 .

 

1-      Demographic data and descriptive statistics for the study variables

The study participant's age distribution ranged from 3 to 17 years old with mean age of 9.38±4.2. Descriptive statistics for sex,   conditioning, exposure to acute GVHD, fate of acute GVHD, stem cells source (SC) and cGVHD were described in (Table 1).

Table (1): Descriptive statistics to study variables

Sex

Male

31

66.00%

Female

16

34.00%

MAC/RIC related to conditioning

MAC

38

80.90%

RIC

9

19.10%

SC source

BM

8

17.80%

PB

39

83.00%

range of CD 34

normal

32

69.60%

high

14

30.40%

acute GVHD

Yes

16

34.80%

No

30

65.20%

Chronic GVHD (at least single site affection)

Yes

32

68.08

No

15

31.9%

 

RIC: Reduced Intensity Conditioning (uses less chemotherapy and radiation than standard myeloablative conditioning regimen)

MAC: myeloablative conditioning refers to (administration of total body irradiation)

PB: peripheral blood

BM: bone marrow

 

2-      Prevalence of chronic oral  graft versus disease

Regarding objective clinical findings, we observed the oral manifestation of GVHD (mucosal lesions, diminished salivary flow and restricted mouth opening). We found that the number of  patients with oral cGVHD (at least 1 oral manifestation)  in relation to the whole study population was 26 (55.3%), 15 patients clinically represented with chronic oral mucosal GVHD, 10 with diminished salivary flow and 22 with restricted mouth opening (Table 2). Combined oral lesions in the study group 14 patients (29.7%) have single oral manifestation, 8 patients (17.02%) have the three oral manifestations combined, while 4 patients (8.51%) have only two manifestations combined .

 

Table (2): Showing the distribution of site involvement in cGVHD

Affection site

Count

%

Chronic systemic  GVHD

Spleen ,Chest,Liver

1

4.3%

Spleen

1

4.3%

Skin,Liver

3

13.0%

Skin,GIT

2

8.7%

Skin, GIT, MM

1

4.3%

Skin

10

43.5%

Liver

3

13.0%

GIT

1

4.3%

chest

1

4.3%

Chronic oral GVHD

Mucosal oral chronic versus host disease

Yes

15

31.9%

No

32

68.1%

Salivary Flow

normal

30

63.8%

abnormal

10

21.2 %

Missing

7

14.8%

Maximal mouth opening

normal

24

52.2%

abnormal

22

47.8%

 

 

Regarding the site of mucosal affection, buccal mucosa was affected in 80% of patients with oral mucosal lesions. Other oral mucosal sites included tongue 4%, gingiva7% and labial mucosa 9%. Regarding the clinical presentation of the oral mucosal lesions, 9 patients had erythematous mucosa and white reticular lesion, 4 patients had ulcers and 2 patients had atrophic tongue. (Fig.1).

 Fig 1: Clinical photos of a 6 year male patient, (A) and (B) showing the lichenoid lesions (reticulation and atrophy) in the buccal mucosa bilaterally. (C) showing another male 4 years old patients with the upper and lower lips showing lichenoid changes at the junction of labial mucosa and vermillion border. While , (D) showing the limitation of mouth opening. (E) , (F) showing erythematous lesions and oral ulcers bilaterally on the buccal mucosa of 7 years female patient. (G ) is showing erythema and psudomembrane in the left buccal mucosa of 6 years old male patient. (H) showing lichenoid changes in the vermillion of 12 y male patient and areas of erythema and ulceration are appearing in left buccal mucosa and the tongue in addition to sever limitation of mouth opening ,(I) is showing the skin affection in the same patient.

 

3-      Relation between oral cGVHD and systemic affection

Out of 32 cGVHD patients, 17 patients (53.1%) had combined oral and systemic cGVHD,

6 patients (18.7%) had only systemic involvement, while 9 patients (28.1%) had only oral involvement (table 3). There is a statistically significant association between oral involvement and systemic involvement in patients with cGVHD where P value < 0.05 (Table 3).

We observed that 11 patients out of 26 patients with oral cGVHD (42.3%) had skin manifestations.

 

 

Table (3): Results chi- square test comparing appearance of oral cGVHD and systemic involvement

 

 

Oral cGVHD

 

Yes

No

P value

Count

%

Count

%

 

Systemic involvement

Yes

17

65.3%

6

28.57%

0.012*

No

9

34.6%

15

71.42%

 *P-value significant at < 0.05

 

 

4-      Association of the oral manifestations of cGVHD and the study variables

No association was detected between oral manifestations and age, sex, transplant type, source of stem cells or occurrence of acute GVHD.  However, association was significant between the trio oral manifestations (mucosal ,diminished salivary flow and restricted mouth opening) where the combined lesions out of the total patients with oral cGVHD was 12 patients (46.1%)(Tables 4,5,6,7).

 

Table (4): Results of Mann-Whitney test for comparing appearance of oral cGVHD manifestations and the age of  the child

 

 

Oral mucosal cGVHD

 

Yes

No

Mean

SD

Median

Minimum

Maximum

Mean

SD

Median

Minimum

Maximum

P value

Age (y)

8.13

4.37

9.00

3.00

17.00

9.97

4.19

10.00

3.00

17.00

0.15

Salivary flow rate

 

Normal

Diminished

Mean

SD

Median

Minimum

Maximum

Mean

SD

Median

Minimum

Maximum

P value

10.17

3.95

10.00

3.00

17.00

8.00

4.57

7.50

3.00

17.00

0.167

Mouth opening

 

Normal

Restricted

Mean

SD

Median

Minimum

Maximum

Mean

SD

Median

Minimum

Maximum

P value

10.33

4.35

10.00

3.00

17.00

8.45

4.17

9.00

3.00

17.00

0.178

                             

 *P-value significant at < 0.05

 

 

 

 

 

Table (5): Results of chi- square test comparing appearance of oral mucosal cGVHD and qualitative study variables

 

 

oral mucosal cGVHD

 

Yes

No

P value

Count

%

Count

%

 

Sex

M

10

66.7%

21

65.6%

0.944

F

5

33.3%

11

34.4%

MAC/RIC related to conditioning

MAC

12

80.0%

26

81.3%

1

RIC

3

20.0%

6

18.8%

SC source

BM

1

6.7%

7

21.9%

0.406

PB

14

93.3%

25

78.1%

Range of CD 34

Normal

10

71.4%

22

68.8%

1

High

4

28.6%

10

31.3%

Acute GVHD

Yes

7

46.7%

9

29.0%

0.239

NO

8

53.3%

22

71.0%

Acute GVHD Fate

Responder

4

57.1%

8

88.9%

0.262

Refractory

3

42.9%

1

11.1%

Salivary Flow

Normal

2

20.0%

28

93.3%

* 0.001

Diminished

8

80.0%

2

6.7%

Maximal mouth opening

Normal

2

14.3%

22

68.8%

*0.001

Restricted

12

85.7%

10

31.3%

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

*P-value significant at < 0.05

 

 

Table (6): Results chi- square test comparing change in salivary flow rate and qualitative study variables.

 

 

 

 

 

Salivary Flow

 

Normal

Diminished

P value

Count

%

Count

%

 

Sex

M

21

70.0%

6

60.0%

0.700

F

9

30.0%

4

40.0%

MAC/RIC related to conditioning

MAC

26

86.7%

9

90.0%

1

RIC

4

13.3%

1

10.0%

SC source

BM

4

13.3%

2

20.0%

0.629

PB

26

86.7%

8

80.0%

range of CD 34

normal

20

66.7%

8

80.0%

0.693

High

10

33.3%

2

20.0%

acute GVHD

Yes

9

31.0%

3

30.0%

1

NO

20

69.0%

7

70.0%

acute GVHD Fate

Responder

8

88.9%

2

66.7%

0.455

Refractory

1

11.1%

1

33.3%

Mucosal oral cGVHD

Yes

2

6.7%

8

80.0%

< 0.001*

No

28

93.3%

2

20.0%

Maximal mouth opening

normal

20

66.7%

1

10.0%

0.003*

abnormal

10

33.3%

9

90.0%

 

*P-value significant at < 0.05

 

 

Table (7): Results chi- square test comparing change in length of mouth opening and qualitative study variables

 

 

Maximal mouth opening

 

normal

abnormal

P value

Count

%

Count

%

 

Sex

M

17

70.8%

13

59.1%

0.404

F

7

29.2%

9

40.9%

MAC/RIC related to conditioning

MAC

17

70.8%

21

95.5%

0.049

RIC

7

29.2%

1

4.5%

SC source

BM

4

16.7%

4

18.2%

1

PB

20

83.3%

18

81.8%

range of CD 34

normal

16

66.7%

16

76.2%

0.482

High

8

33.3%

5

23.8%

acute GVHD

Yes

6

26.1%

10

45.5%

0.175

NO

17

73.9%

12

54.5%

acute GVHD Fate

Responder

4

66.7%

8

80.0%

0.604

Refractory

2

33.3%

2

20.0%

Mucosal oral cGVHD

Yes

2

8.3%

12

54.5%

0.001*

No

22

91.7%

10

45.5%

Salivary Flow

normal

20

95.2%

10

52.6%

0.003*

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

*P-value significant at < 0.05

 

 


 

 

Discussion

 

The lack of studies discussing the prevalence of oral GVHD in Egypt is quite evident that to our knowledge, our study is the first study that investigates the prevalence of oral chronic GVHD in a population of Egyptian pediatric patients after allogeneic HSCT.

NIH consensus project (2005) defined the diagnostic criteria of oral cGVHD , criteria include oral mucosal cGVHD, diminished salivary flow and fibrosis of the peri-oral tissues additionally some other associated lesions for instance mucoceles, candidiasis and  pseudo membranes formation Filipovich (2005).

The study population consisted of 47 patients who underwent allogeneic HSCT 31 males and 16 females, the vast majority of these patients received peripheral blood stem cells (PBSCT) (83.0%).

The age distribution of the participants of the study ranged from 3 to 17 years old with mean age of 9.38y ±4.2y. We observed that in the literature there are few studies that tackled the oral cGVHD in children Berkowitz (1987), Dahllof et al. (1988), Dahllöf et al. (1989) ,Nicolatou-Galitis et al. (2001), Treister et al. (2005). In agreement with our finding on pediatric patients is Berkowitz (1987) who found that mean age in the study group was 9.3 (7 mo -10y). Similarly, Dahllof et al. (1988) and Dahllöf et al. (1989) found that mean age in the study group was 7y (1-12). Also, Nicolatou-Galitis et al. (2001) found that mean age in the study group was 10.7 y (1.5-15).

 Furthernore, in the present study the prevalence of oral GVHD related to sex distribution was more common in males (66.0%) than females (34.0%), which seems to be in agreement with other studies that investigated the oral cGVHD in pediatric patients establishing that male predominance was detected Berkowitz et al. (1987) Dahllof et al. (1988) Nicolatou-Galitis et al. (2001).

Our study revealed that chronic GVHD was developed by 68.08% of patients  after transplantation with 55.3% of them  having oral involvement.

This is in accordance with Hull et al. (2011). The study done at Westmead Hospital BMTU in Australia, sample consisted of 88 adults who underwent allogeneic HSCT assessing the prevalence of oral long-term complications. Chronic GVHD was detected in 72% of the subjects after transplantation with 56% of the subjects suffered from oral manifestations Hull et al. (2011).

Similarly, our results are consistent with Imanguli et al. (2006) who found that the oral cavity is affected in 70% of those who have undergone hematopoietic stem cell transplantation.

In another study, lima et al. (2012), cGVHD was observed in 32.5% (13/40) of the patients undergoing allogeneic bone marrow transplantation  and about  50%of all the patients showed oral involvement  (25/51; 49%). Some patients had manifested combined oral lesions.

In addition, a study done by Treister et al. (2005) in a pediatric cohort, for each child subjective and objective assessments of mucosal, salivary gland function, and oral sclerosis were done.  Oral mucosal cGVHD was diagnosed in 22 (45%) of 49 patients. Only 4 (8%) of 49 patients reported painful mouth. However, in contrast to our findings, subjective and objective salivary gland and sclerotic diseases were observed far less often.

In contrast to our results, Berkowitz et al. (1987) found that prevalence of oral cGVHD was (20%) 8/41 pediatric patients who underwent HSCT. Similarly,  the study conducted by Dahllof et al. (1988, 1989) showed the prevalence of oral cGVHD (20%) 9/45 pediatric patients. Also, Nicolatou-Galitis et al. (2001) detected (10%) only 9 patients with oral cGVHD out of 90 patients screened for cGVHD. These studies diagnosed the oral cGVHD based on having mucosal oral lesions and xerostomia defined either as diminished salivary flow Dahllof et al. (1988, 1989) or with clinical signs of oral dryness as in Berkowitz et al. (1987) and Nicolatou-Galitis et al. (2001). All of them did not consider the limitation of mouth opening in diagnosing the oral cGVHD explaining the difference in our results.

Diagnosis of oral signs and symptoms in children is more difficult than in adults, as clinical examinations can be challenging in some patients Treister et al. (2005). As seen in  our study  we missed the salivary flow measurement of 7 patients as they could not follow the instruction of saliva collection.   

Regarding the mucosal clinical  presentation, we seem to be in agreement with Schubert et al. (2008) who studied patients in age range of  3 to 41 years and found that the most common clinical findings were erythema, atrophy or lichenoid lesions appearing on  the buccal and labial  mucosae. Also, clinical presentations and site distribution detected in many studies Filipovich et al. (2005) and Pavletic et al. (2006) are in agreement with our findings.

In contrast to our finding in predicting risk factors, an association with transplant type have been previously proposed, where a higher degree of oral involvement (70%) seen in peripheral blood stem cell transplant relative to bone marrow transplant (53%)  Pavletic et al. (2005). In addition, considering the age as risk factor  Storb et al. (1983) and Carlens et al. (1998) found that younger patients are considered to have a decreased risk of chronic GVHD.

Concerning the dose of CD34, human hematopoietic stem cells expressing CD34 have the ability to bind  E-selectin guiding  the migration to specialized the bone marrow vascular bed  expressing the  vascular selectins , maximizing the good results after transplantation. Zaucha et al. (2001)

There is a controversy concerning whether to restrict the dose of infused CD34 cells/kg in recipients of both related and unrelated donor grafts. The effect of higher CD34 cell dose in the graft on the risk of cGVHD is debatable Zaucha et al. (2001). In adults, as some studies have revealed , there are only diverse associations Przepiorka et al.(2001) or none at all  Cao et al , (2005) and Pulsipher et al. (2009). Increasing the risk of GVHD is considered  the major concern when higher doses of CD34 cells present in the graft.  In children, consistent with our findings is Kałwakw et al, (2010) who have found absolutely no correlation between the CD34 cell dose and the incidence of severe aGVHD and cGVHD.

Regarding  statistical association between the trio oral manifestation (mucosal lesion, diminished salivary flow and restricted mouth opening) that was detected in our study, it is considered consistent with findings of  Bassim et al. (2014) and  confirming the diagnostic criteria of oral cGVHD established in 2005 at National Institutes of Health Consensus about diagnosis and staging of cGVHD Filipovich et al. (2005).

Unfortunately, the small sample size is considered a limitation in our study; therefore, further studies are recommended on a larger sample size.

Finally, The high prevalence of oral cGVHD among the children underwent bone marrow transplantation in Egypt suggests that oral medicine specialists should have an active participation  in the long-term follow-up of these patients for  proper management of oral cGVHD.

 


 

 

Conclusion

In a sample of Egyptian pediatric patients who underwent bone marrow transplantation, the prevalence of cGVHD is 68.08%, patients with oral cGVHD is 55.3%. No association was detected between oral manifestations and age, sex, transplant type, source of stem cells or occurrence of acute GVHD. There was significant association between systemic and oral manifestations mainly skin, conditioning regimen and diminished salivary flow and between the trio oral manifestations where the combined lesions out of the total patients with oral cGVHD was 12 patients (46.1%).

 


 

 

1-      Arai S, Arora M, Wang T, Spellman SR, He W, Couriel DR, et al (2015): Increasing incidence of chronic graft-versus-host disease in allogeneic transplantation: a report from the Center for International Blood and Marrow Transplant Research. Biol Blood Marrow Transplant.;21:266–74
2-      Bassim CW, Fassil H, Dobbin M, Steinberg SM, Baird K, Cole K, Joe G, Comis LE, et al. (2014): Malnutrition in patients with chronic GVHD. Bone Marrow Transplant. 49:1300–1306.
3-      Berkowitz, R.J., Strandjord, S., Jones, P., Hughes, C., Barsetti, J., Gordon, E.M., Cheung, N.K., Warkentin, P. and Coccia, P.F., (1987): Stomatologic complications of bone marrow transplantation in a pediatric population. Pediatr Dent  9(2). pp.105-10.
4-      Cao TM, Wong RM, Sheehan K, Laport, G. G., Stockerl-Goldstein, K. E., Johnston, L. J., Lowsky, R et al.( 2005): CD34, CD4, and CD8 cell doses do not influence engraftment, graft-versus-host disease, or survival following myeloablative human leukocyte antigen-identical peripheral blood allografting for hematologic malignancies. Exp Hematol. 33:279-285.
5-      Carlens, S., Ringdén, O., Remberger, M., Lönnqvist, B., Hägglund, H., Klaesson, et al. (1998): Risk factors for chronic graft-versus-host disease after bone marrow transplantation..  22(8), pp.755-761.
6-      Dahllöf, G., Heimdahl, A., Bolme, P., Lönnqvist, B. and Ringden, O., (1988): Oral condition in children treated with bone marrow transplantation. Bone marrow transplantation, 3(1), pp.43-51.
7-      Dahllöf, G., Heimdahl, A., Modéer, T., Twetman, S., Bolme, P. and Ringdén, O., (1989) : Oral mucous membrane lesions in children treated with bone marrow transplantation. European Journal of Oral Sciences, 97(3). pp.268-277.
Duarte, R.F., Labopin, M., Bader, P, Basak GW, Bonini C, Chabannon C.et al (2019): Indications for haematopoietic stem cell transplantation for haematological diseases, solid tumours and immune disorders: current practice in Europe. Bone Marrow Transplant 54, 1525–1552.
8-      Fassil H, Bassim CW, Mays J, Edwards D, Baird K, Steinberg SM, Williams KM, et al. (2012): Oral chronic graft-vs.-host disease characterization using the NIH scale. J Dent Res. 91(7 Suppl):45S–51S
9-      Filipovich, A. H., Weisdorf, D., Pavletic, S., Socie, G., Wingard, J. R., Lee, S. J., Martin, P., et al (2005): National Institutes of Health Consensus Development Project on criteria for clinical trials in chronic graft-versus-host disease: I. diagnosis and staging working group report. In Biology of Blood and Marrow Transplantation. 11(12), pp. 945–56.
10-  Forcella L, Filippi C, Waltimo T, Filippi A (2018): Measurement of unstimulated salivary flow rate in healthy children aged 6 to 15 years. Swiss Dent J. 10;128(12):962-967.
11-  Grube M, Holler E, Weber D, Holler B, Herr W, Wolff D. (2016): Risk Factors and Outcome of Chronic Graft-versus-Host Disease after Allogeneic Stem Cell Transplantation-Results from a Single-Center Observational Study. Biol Blood Marrow Transplant. Oct;22(10):1781-1791.
12-  Hull, K & Kerridge, Ian & Schifter, Mark. (2011): Long-term oral complications of allogeneic haematopoietic SCT. Bone marrow transplantation. 47. 265-70. 10.1038/bmt.2011.63.
13-  Imanguli, M.M., Pavletic, S.Z., Guadagnini, J.P., Brahim, J.S. and Atkinson, J.C. (2006): “Chronic Graft versus Host Disease of Oral Mucosa: Review of Available Therapies.” Oral Surgery, Oral Medicine, Oral Pathology, Oral Radiology and Endodontology. 101(2), pp.175-183.
14-  Juric MK, Ghimire S, Ogonek J, Weissinger EM, Holler E, van Rood JJ et al. (2016): Milestones of Hematopoietic Stem Cell Transplantation - From First Human Studies to Current Developments. Front Immunol. Nov 9:470-77.
15-  Kałwak K, Porwolik J, Mielcarek M, Gorczyńska E, Owoc-Lempach J, Ussowicz M, et al. (2010): Higher CD34(+) and CD3(+) cell doses in the graft promote long-term survival, and have no impact on the incidence of severe acute or chronic graft-versus-host disease after in vivo T cell-depleted unrelated donor hematopoietic stem cell transplantation in children. Biol Blood Marrow Transplant.16(10):1388-401.
16-  Lima, E.D.N. & Fernandes, Maria & Ferreira, Maria & Nonaka, Cassiano & Freitas, Roseana & Medeiros, Ana. (2012): Bone marrow transplantation: Graft versus host disease and oral changes. Revista Odonto Ciencia. 27. 10-15. 10.1590/S1980-65232012000100002.
17-  Mahmoud H, El-Haddad A, Fahmy O, El-Emary M, Nassar A, Abdel-Mooti M, Sobhy A, Sultan A (2008):Hematopoietic stem cell transplantation in Egypt. Bone Marrow Transplant;42 Suppl 1:S76-S80.
18-  Mahmoud HK, Fathy GM, Elhaddad A, Fahmy OA, Abdel-Mooti M, Abdelfattah R, Bokhary M (2020): Hematopoietic Stem Cell Transplantation in Egypt: Challenges and Opportunities. Mediterr J Hematol Infect Dis. May 1;12(1):e2020023.
19-  Meier JK, Wolff D, Pavletic S, Greinix H, Gosau M, Bertz H, Lee SJ, Lawitschka A, Elad S. (2011):  International Consensus Conference on Clinical Practice in cGVHD. Oral chronic graft-versus-host disease: report from the International Consensus Conference on clinical practice in cGVHD. Clin Oral Investig. 15(2):127–139.
20-  Müller, L., van Waes, H., Langerweger, C., Molinari, L. and Saurenmann, R.K. (2013):  Maximal mouth opening capacity: percentiles for healthy children 4–17 years of age. Pediatric Rheumatology, 11(1), pp.1-7.N.
21-  Nicolatou‐Galitis, O., Kitra, V., Van Vliet‐Constantinidou, C., Peristeri, J., Goussetis, E., Petropoulos, D. and Grafakos, S., (2001): The oral manifestations of chronic graft‐versus‐host disease (cGVHD) in paediatric allogeneic bone marrow transplant recipients. Journal of oral pathology & medicine, 30(3), pp.148-153.
22-  Passweg JR, Baldomero H, Bader P, Bonini C, Cesaro S, Dreger P, Duarte RF et al (2016): Hematopoietic stem cell transplantation in Europe 2014: more than 40 000 transplants annually. Bone Marrow Transplant. Jun;51(6):786-92.
23-  Pavletic, S.Z., Smith, L.M., Bishop, M.R., Lynch, J.C., Tarantolo, S.R., Vose, J.M., Bierman, P.J., Hadi, A., Armitage, J.O. and Kessinger, A. (2005). Prognostic factors of chronic graft-versus-host disease after allogenic blood stem-cell transplantation. American Journal of Hematology: 78(4), pp. 265-274
24-  Phelan, R., Arora, M., Chen, M. (2020): Current use and outcome of hematopoietic stem cell transplantation: CIBMTR US summary slides
25-  Przepiorka D, Anderlini P, Saliba R, aliba, R., Cleary, K., Mehra, R., Khouri, Champlin, R et al. (2001): Chronic graft-versus host disease after allogeneic blood stem cell transplantation. Blood. 98:1695-1700.
26-  Pulsipher MA, Chitphakdithai P, Logan BR, Leitman SF, Anderlini P, Klein JP, Horowitz MM et al.(2009): Donor, recipient, and transplant characteristics as risk factors after unrelated donor PBSC transplantation: beneficial effects of higher CD341 cell dose. Blood. 114:2606-2616.
27-  Schubert MM, Correa ME. (2008): Oral graft-versus-host disease. Dent Clin North Am. 52(1):79–109
28-  Storb, R., Prentice, R. L., Sullivan, K. M., Shulman, H. M., Deeg, H. J., Doney, K. C., Buckner, C. D, et al. (1983): Predictive factors in chronic graft-versus-host disease in patients with aplastic anemia treated by marrow transplantation from HLA-identical siblings. Annals of Internal Medicine. 98(4), pp.461-466.
29-  Sureda, A., Bader, P., Cesaro, S., Duarte , R F, Dufour C et al. (2015):  Indications for allo- and auto-SCT for haematological diseases, solid tumours and immune disorders: current practice in Europe, Bone Marrow Transplant 501037–1056
30-  Treister, N.S., Cook Jr, E.F., Antin, J., Lee, S.J., Soiffer, R. and Woo, S.B.(2008): Clinical evaluation of oral chronic graft-versus-host disease. Biology of Blood and Marrow Transplantation, 14(1), pp.110-115.
31-  Treister, N.S., Woo, S.B., O’Holleran, E.W., Lehmann, L.E., Parsons, S.K. and Guinan, E.C., (2005): Oral chronic graft-versus-host disease in pediatric patients after hematopoietic stem cell transplantation. Biology of Blood and Marrow Transplantation, 11(9), pp.721-731.
32-  Walter A. Bretz, Eduardo V. do Valle, Jed J. Jacobson, Fernanda Marchi, Suely Mendes, et al.(2001): Unstimulated salivary flow rates of young children. 91(5), pp.541-545.
33-  Zaucha JM, Gooley T, Bensinger WI, Heimfeld S, Chauncey TR, Zaucha R, Martin PJet al.(2001): CD34 cell dose in granulocyte colony-stimulating factor-mobilized peripheral blood mononuclear cell grafts affects engraftment kinetics and development of extensive chronic graft-versus-host disease after human leukocyte antigen-identical sibling transplantation. Blood. 98:3221-3227.